F2i

Indicaton

F2i is a first-in-class, non-kinase, protein-protein interaction inhibitor of aberrant fibroblast growth factor signalling pathway in invasive cancers

Therapeutic indications

Oncology

Type of product

Small molecule

Table

Phase

Discovery
Partnering status

Not partnered

You may also be interested in

3D CoSeedis in chip Assays

Preclinical 3D Study models for oncology and neurology.

Marketed

MV-004

MV-004 is an orally available recombinant bacterial enzyme acting in the small intesine to adaptively modulate microbiota function during cancer immunotherapy. MV004 has been conceived to convert the majority of patients with solid tumors non-responding to immune checkpoint blockade (ICB) to responders.

Discovery

4D Lifetest Lung Dx, 4D Lifetest Breast Dx, 4D Lifetest Colon Dx, 4D Lifetest Prostate Dx

4D Lifetest™ is our flagship product and the first non-invasive CE IVD certified blood liquid biopsy assay to assess cancer formation due to its unique transformational biomarker at its earliest stage. This diagnostic information enables eraly invention and is a breakthrough progress to reduce mortality rates of cancer patients and protect benign patients from the invasive stress of frequently repeated surveillance diagnostics.The assay is CE IVD certified for the early detection of lung, breast, prostate and colon cancer and comercially available via our commercialization partner Medicover.

Marketed

F2i

Indicaton

Therapeutic indications

Type of product

Company

Table

You may also be interested in

3D CoSeedis in chip Assays

MV-004

4D Lifetest Lung Dx, 4D Lifetest Breast Dx, 4D Lifetest Colon Dx, 4D Lifetest Prostate Dx